Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01147744 · ClinicalTrials.gov registry record · Phase 2
Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administered Once Daily
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 700
- Enrollment target
NCT01147744 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 700 participants.
The verdict
NCT01147744, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 700 participants
- Enrollment target
Study Summary
To evaluate the efficacy, dose response and safety of four doses of GSK2190915 in tablet form (10mg, 30mg, 100mg and 300mg) administered once daily, over 8 weeks compared with placebo in adolescent and adult subjects (12 years of age and older) with persistent asthma. These data will form the basis for the selection of the optimal daily dose of GSK2190915 to be carried forward in Phase III asthma studies. The study also includes Fluticasone Propionate Inhalation Powder (100 mcg, twice daily) and Montelukast (10mg, once daily) to allow for an exploratory analysis of the efficacy of GSK2190915 versus a low dose inhaled corticosteroid and a leukotriene receptor antagonist.
Interventions
- DRUG Fluticasone Propionate 100mcg via ACCUHALER/DISKUS
- DRUG GSK2190915 100mg
- DRUG GSK2190915 10mg
- DRUG GSK2190915 300mg
- DRUG GSK2190915 30mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 2010-06-28 |
| Est. Completion | 2011-10-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01147744
The ClinicalTrials.gov registry entry for NCT01147744 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 700 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Fluticasone Propionate 100mcg via ACCUHALER/DISKUS is the first listed.
NCT01147744 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01147744 about?
NCT01147744 is a clinical study titled "Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administered Once Daily". To evaluate the efficacy, dose response and safety of four doses of GSK2190915 in tablet form (10mg, 30mg, 100mg and 300mg) administered once daily, over 8 weeks compared with placebo in adolescent and adult subjects (12 years of age and older) with persistent asthma. These data will form the basis ...
What is the current status of trial NCT01147744?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 700 participants. The study started on 2010-06-28. Estimated completion is 2011-10-06.
What interventions are being tested in trial NCT01147744?
The interventions under investigation include: Fluticasone Propionate 100mcg via ACCUHALER/DISKUS (DRUG), GSK2190915 100mg (DRUG), GSK2190915 10mg (DRUG), GSK2190915 300mg (DRUG), GSK2190915 30mg (DRUG).
Who is sponsoring clinical trial NCT01147744?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.